Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 5Phase 1 4Phase 1/2 2Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Other neoplasm 1

Conditions

Neoplasms 2009Carcinoma, Non-Small-Cell Lung 1222Breast Neoplasms 1214Leukemia, Myeloid, Acute 965Neoplasm Metastasis 900Melanoma 777Colorectal Neoplasms 749Lymphoma 725Multiple Myeloma 723Ovarian Neoplasms 673Pancreatic Neoplasms 664Prostatic Neoplasms 657Lymphoma, Non-Hodgkin 657Recurrence 636Precursor Cell Lymphoblastic Leukemia-Lymphoma 583Lung Neoplasms 559Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 485Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Brain Neoplasms 413Squamous Cell Carcinoma of Head and Neck 388Stomach Neoplasms 386Carcinoma, Renal Cell 384Myelodysplastic Syndromes 381Carcinoma, Hepatocellular 367Advanced Solid Tumors 356Lymphoma, Mantle-Cell 345Glioma 342

Interventions

Docetaxel 2palbociclib 1nirogacestat 1Trastuzumab 1Rogaratinib 1Fulvestrant 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Breast Cancer Metastatic × Clear all
NCT04509596 2025-04-01

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Dizal Pharmaceuticals

Phase 1 Completed
23 enrolled
Breast

Breast Cancer Metastatic

NCT04483505 2023-12-28

ROGABREAST

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1 Completed
9 enrolled
BreastOther neoplasm

Breast Cancer Metastatic

NCT05301530 2022-03-29

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 1 Completed
50 enrolled
Breast

Breast Cancer Metastatic

NCT01876251 2019-03-15

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Pfizer

Phase 1 Terminated
30 enrolled 29 charts
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡